Bronchial Asthma
Conditions
Interventions
Benralizumab is given subcutaneously
Sponsors
Department of Respiratory Medicine, University of Occupational and Environmental Health, Japan
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients receiving oral corticosteroid daily 2. Patients with increasing of corticosteroid or needing corticosteroid temporalily at least twice a year due to asthma exacerbation 3. Patients with ACT<25 or ACQ>0
Exclusion criteria
Exclusion criteria: 1. Patients with intention to refuse to participate in this research. 2.Patients with a history of hypersensitivity to this drug and the ingredients of this drug. 3. Patients under 20 years old. 4. Patients who may be pregnant. 5. Patients with breastfeeding 6. Patients deemed ineligible by the attending physicians for various reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Spirometry | — |
Secondary
| Measure | Time frame |
|---|---|
| Astma Control Test(ACT), Asthma Control Questionnaire(ACQ), Asthma Quality of Life Questionnaire(AQLQ), FeNO, Objective opinion, Sputum eosinophil counts, Chest X-ray, Chest CT, Respiratory resistance test, Oral corticosteroid dose, Absence of unexpected visit and hospitalization due to asthma exacerbation, Clinical examination, Sinus CT, Safety | — |
Countries
Japan
Contacts
Public ContactTakashi Tachiwada
University of Occupational and Environmental Health, Japan Department of Respiratory Medicine
Outcome results
None listed